Company Overview and News

 
Amidst Strong Quarterly Growth, Novartis Receives FDA Complete Response Letter for Canakinumab

2018-10-18 biospace
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for canakinumab as a potential treatment for cardiovascular risk reduction.
AUROPHARMA 524804 ARBQY

1
HDFC Bank, LT Infotech among top 5 momentum plays for 5-15% returns

2018-10-16 moneycontrol
The equity market opened on a cautious note but managed to close in the positive after buying in last hour of trade on October 15. It was a volatile session of trade for Nifty but it managed to close at 10,512 up by 0.38 percent.
SIFLY 523756 SRI AUROPHARMA HDB SREINFRA 524804 500180 ARBQY HDFCBANK SRIA

 
Outbound activity drives Merger and Acquisition’s robust growth in Q3 of 2018

2018-10-15 financialexpress
Merger and acquisition (M&A) deal values recorded a 5.3-times increase year-on-year (y-o-y) in the third quarter of calendar year 2018 (Q32018) driven by outbound activity, according to a dealtracker report by Grant Thornton. The report stated that M&A deal values stood at $11.506 billion in Q32018 compared with $2.147 billion in the same period last year.
CNACU AUROPHARMA 524804 ARBQY CNAC

 
UPDATE 1-EU places China's Zhejiang Huahai under increased supervision

2018-10-15 reuters
(Reuters) - European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.
AUROPHARMA 524804 ARBQY

 
India Inc#39;s Jan-Sep MA deal tally touch $76 bn: Report

2018-10-15 moneycontrol
Corporate India announced merger and acquisitions (M&As) worth $11.5 billion in the third quarter of this year, following which the January-September deal tally stood at $76.03 billion, says a report.
BHRYY CNACU AUROPHARMA 534816 524804 ARBQY CNAC INFRATEL

 
USFDA releases guidance to help generic drug makers copy complex ones

2018-10-12 moneycontrol
As part of its efforts to promote generic competition and reduce healthcare costs, the USFDA has released guidance documents to advance the development of copycats for complex drugs.
532321 AUROPHARMA NATCOPHARM 524804 ARBQY 524816 CDLYY CADILAHC

1
Aurobindo Pharma to produce, market oral syrup in US

2018-10-11 thehindubusinessline
Aurobindo Pharma Ltd Thursday said it would be making and marketing azithromycin oral suspension in the US market after getting final approval from the US Food and Drug Administration (USFDA). The oral suspension is to treat mild-to-moderate infections, a press release said here.
PFZ AUROPHARMA 524804 ARBQY 500680 PFE PFIZER

1
Aurobindo Pharma slips 3%; gets USFDA approval for anti-infection drug

2018-10-11 moneycontrol
Shares of Aurobindo Pharma slipped 3 percent intraday Friday. The company has received USFDA Approval for Azithromycin Oral Suspension.
PFZ AUROPHARMA 524804 ARBQY 500680 PFE PFIZER

 
Aurobindo Pharma gets USFDA nod for infections treatment drug

2018-10-11 moneycontrol
Drug firm Aurobindo Pharma on Thursday said it has received final nod from the US health regulator for its Azithromycin oral suspension used for treatment of infections.
AUROPHARMA 524804 ARBQY

 
Aurobindo Pharma Limited - Press Release

2018-10-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

 
Broker's Call: Aurobindo Pharma (Buy)

2018-10-09 thehindubusinessline
Aurobindo Pharma is one of the few large generic players to post growth in its US business, whereas similar-sized portfolios have witnessed significant erosion. With near-term opportunities such as Toprol XL, Prevacid ODT, Welchol, and several injectable products, we believe APL could continue to maintain its growth momentum.
GRASIM GRSXY GRSJY AUROPHARMA 524804 ARBQY 500300

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...